A citation-based method for searching scientific literature

Howard I Scher, Karim Fizazi, Fred Saad, Mary-Ellen Taplin, Cora N Sternberg, Kurt Miller, Ronald de Wit, Peter Mulders, Kim N Chi, Neal D Shore, Andrew J Armstrong, Thomas W Flaig, Aude Fléchon, Paul Mainwaring, Mark Fleming, John D Hainsworth, Mohammad Hirmand, Bryan Selby, Lynn Seely, Johann S de Bono. N Engl J Med 2012
Times Cited: 3022

Karim Fizazi, Neal Shore, Teuvo L Tammela, Albertas Ulys, Egils Vjaters, Sergey Polyakov, Mindaugas Jievaltas, Murilo Luz, Boris Alekseev, Iris Kuss, Christian Kappeler, Amir Snapir, Toni Sarapohja, Matthew R Smith. N Engl J Med 2019
Times Cited: 386

List of shared articles

Times cited

Disparities in germline testing among racial minorities with prostate cancer.
Nicole Weise, Justin Shaya, Juan Javier-Desloges, Heather H Cheng, Lisa Madlensky, Rana R McKay. Prostate Cancer Prostatic Dis 2022

[Development of a therapeutic education program for prostate cancer patients undergoing new generation hormone therapy].
Alice Cuenant, Isabelle Eglin, Virginia Ferreira, Nadine Houédé. Bull Cancer 2022

Dendritic cell-based vaccine prolongs survival and time to next therapy independently of the vaccine cell number.
Simon Hawlina, Helena H Chowdhury, Tomaž Smrkolj, Robert Zorec. Biol Direct 2022

Metastasis Model to Test the Role of Notch Signaling in Prostate Cancer.
Shiqin Liu, En-Chi Hsu, Michelle Shen, Merve Aslan, Tanya Stoyanova. Methods Mol Biol 2022

Neutropenia, neutrophilia, and neutrophil-lymphocyte ratio as prognostic markers in patients with metastatic castration-resistant prostate cancer.
Alexander Meisel, Ronald de Wit, Stephane Oudard, Oliver Sartor, Frank Stenner-Liewen, Zhenming Shun, Meredith Foster, Ayse Ozatilgan, Mario Eisenberger, Johann S de Bono. Ther Adv Med Oncol 2022

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer.
R Kanesvaran, E Castro, A Wong, K Fizazi, M L K Chua, Y Zhu, H Malhotra, Y Miura, J L Lee, F L T Chong,[...]. ESMO Open 2022

Targeting the androgen receptor signaling pathway in advanced prostate cancer.
Clement Chung, Karen Abboud. Am J Health Syst Pharm 2022

Rational Second-Generation Antiandrogen Use in Prostate Cancer.
Jacob J Orme, Lance C Pagliaro, J Fernando Quevedo, Sean S Park, Brian A Costello. Oncologist 2022

Metastatic Prostate Cancer: Treatment Options.
Vérane Achard, Paul Martin Putora, Aurelius Omlin, Thomas Zilli, Stefanie Fischer. Oncology 2022

SU086, an inhibitor of HSP90, impairs glycolysis and represents a treatment strategy for advanced prostate cancer.
Meghan A Rice, Vineet Kumar, Dhanir Tailor, Fernando Jose Garcia-Marques, En-Chi Hsu, Shiqin Liu, Abel Bermudez, Vijayalakshmi Kanchustambham, Vishnu Shankar, Zintis Inde,[...]. Cell Rep Med 2022

Androgen Deprivation Therapy in High-Risk Localized and Locally Advanced Prostate Cancer.
Hiroaki Iwamoto, Kouji Izumi, Tomoyuki Makino, Atsushi Mizokami. Cancers (Basel) 2022

Hormone Treatment of Prostate Cancer:: Evidence for Usage and Safety.
Muhieddine Labban, Marwan Alkassis, Khalid Alkhatib, Logan Briggs, Alexander P Cole, Adam S Kibel, Quoc-Dien Trinh. Urol Clin North Am 2022

Targeting signaling pathways in prostate cancer: mechanisms and clinical trials.
Yundong He, Weidong Xu, Yu-Tian Xiao, Haojie Huang, Di Gu, Shancheng Ren. Signal Transduct Target Ther 2022

Second generation androgen receptor antagonists and challenges in prostate cancer treatment.
Yanhua Chen, Qianqian Zhou, William Hankey, Xiaosheng Fang, Fuwen Yuan. Cell Death Dis 2022

Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan.
Akira Yokomizo, Junji Yonese, Shin Egawa, Hiroshi Fukuhara, Hiroji Uemura, Kazuo Nishimura, Masayoshi Nagata, Atsushi Saito, Takumi Lee, Susumu Yamaguchi,[...]. Int J Clin Oncol 2022